Development of a Silica Microparticle Taggant System to Measure ART Adherence
Status:
NOT_YET_RECRUITING
Trial end date:
2025-04-15
Target enrollment:
Participant gender:
Summary
Developing technologies to help measure and provide tools to support medication-taking behaviors (medication adherence) is an important step to ending the human immunodeficiency virus (HIV) epidemic. TruTag Technologies has pioneered the use of a microparticle system that can be incorporated into the coating of medications may help users both identify the medication they are taking and record adherence events. By using a standard smartphone camera, shining light on TruTag-coated medications automatically identifies them to an onboard smartphone app which then indirectly records the adherence event. This study evaluates the real-world usability and feasibility of operating this system among people living with HIV (PLWH).
Phase:
NA
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Gilead Sciences Trutag Technologies
Treatments:
bictegravir, emtricitabine, tenofovir alafenamide, drug combination